<DOC>
	<DOC>NCT02467647</DOC>
	<brief_summary>To investigate the efficacy of the combination of Thalidomide and Huang-Lian-Jie-Du-Tang on the patients with multiple myeloma in maintain therapy.</brief_summary>
	<brief_title>The Effects of Huang-Lian-Jie-Du-Tangï¼ˆHLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Oren gedoku to</mesh_term>
	<criteria>patients can take HLJDT patients can not take HLJDT</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>